Unique ID issued by UMIN | UMIN000040027 |
---|---|
Receipt number | R000045448 |
Scientific Title | A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis |
Date of disclosure of the study information | 2020/04/10 |
Last modified on | 2023/10/10 09:49:47 |
A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis
A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis
A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis
A single-center retrospective observational study evaluating the contribution of platelet volume indices to the response to the treatment with tocilizumab in the patients of rheumatoid arthritis
Japan |
Rheumatoid arthritis
Medicine in general | Clinical immunology |
Others
NO
To evaluate the predictive role of platelet volume indices in the treatment of the patients of RA with tocilizumab.
Others
To evaluate the predictive role of platelet volume indices in the treatment of the patients of RA with tocilizumab.
Exploratory
Others
Not applicable
Relationship between the duration of TCZ usage and platelet volume indices before TCZ administration in the patients with rheumatoid arthritis.
DAS28-ESR, DAS28-CRP, CDAI, and SDAI in the patients of rheumatoid arthritis, observed at three, 12, 36 and 60 months after the initiation of administration of TCZ.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
The patients of rheumatoid arthritis who were diagnosed with the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria or the 1987 ACR criteria at Kansai Medical University Medical center.
The patients of rheumatoid arthritis who were received TCZ at Kansai Medical University Medical center from April 2008 to August 2018.
The patients who lacked adequate medical record.
170
1st name | Nobuyasu |
Middle name | |
Last name | Ishii |
Kansai medical university
First department of international medicine
5708507
Moriguchi-city fumizono-cho 10-15,osaka,japan
+81669921001
ishiinob@takii.kmu.ac.jp
1st name | Nobuyasu |
Middle name | |
Last name | Ishii |
Kansai medical university
First department of international medicine
5708507
Moriguchi-city fumizono-cho 10-15,osaka,japan
+81669921001
ishiinob@takii.kmu.ac.jp
First department of international medicine,Kansai medical university
None
Self funding
None
None
The Institutional Review Board for Clinical Reserch of Kansai Medical University Medcal Center
Moriguchi-city fumizono-cho 10-15,osaka,japan
+81669921001
rinriirb@hirakata.kmu.ac.jp
NO
関西医科大学総合医療センター(大阪府)/Kansai medical university medical center
2020 | Year | 04 | Month | 10 | Day |
https://www.dovepress.com/a-single-center-retrospective-observational-study-evaluating-the-favor-pee
Published
https://www.dovepress.com/a-single-center-retrospective-observational-study-evaluating-the-favor-pee
144
We analyzed the contribution of the base line value of C-reactive protein (CRP) to DCT. We divided the patients with RA into two groups according to a cutoff value of 1.000 mg/dl. In univariate analysis, DCT was significantly increased in patients with a high CRP value (P = 0.0283). Multivariate analysis clearly revealed that a high baseline CRP value was an independent favorable predictive factor for longer DCT (hazard ratio, 0.608, 95% CI: 0.378-0.981, P = 0.0416).
2023 | Year | 10 | Month | 10 | Day |
The medical records of all patients with RA who received treatment with TCZ from April 2008 to August 2018 at Kansai Medical University Medical Center (Moriguchi-City, Japan) were retrospectively reviewed. The clinical diagnosis of RA was made according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria or the 1987 ACR criteria.
Informed consent was obtained in the form of opt-out on the website (http://www.kmu.ac.jp/takii/hospital/scq14r0000000yu1.html)
none
In terms of disease control time (DCT) other than disease remission rate, no obvious predictive factors have been reported. Therefore, we conducted a retrospective observational study to determine how long TCZ controls RA using a statistical technique with a time-to-event analysis.
Completed
2020 | Year | 03 | Month | 01 | Day |
2019 | Year | 12 | Month | 25 | Day |
2020 | Year | 03 | Month | 01 | Day |
2021 | Year | 04 | Month | 30 | Day |
2021 | Year | 04 | Month | 30 | Day |
2021 | Year | 07 | Month | 25 | Day |
2021 | Year | 07 | Month | 25 | Day |
Relationship between the duration of TCZ usage and platelet volume indices before TCZ administration in the patients with rheumatoid arthritis.
2020 | Year | 04 | Month | 01 | Day |
2023 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045448
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |